Remarkable response to pembrolizumab with platinum‐doublet in PD‐L1‐low pulmonary sarcomatoid carcinoma: A case report
Open Access
- 19 February 2021
- journal article
- research article
- Published by Wiley in Thoracic Cancer
- Vol. 12 (7), 1126-1130
- https://doi.org/10.1111/1759-7714.13890
Abstract
Pulmonary sarcomatoid carcinoma (SC) is an aggressive subtype of lung cancer that exhibits resistance to cytotoxic chemotherapy. Although programmed cell death 1 (PD‐1) inhibitors have been reported to show antitumor effects in patients with high programmed death‐ligand 1 (PD‐L1) expressing SC, the efficacy of combined therapy with PD‐1 inhibitor plus cytotoxic chemotherapy has not previously been clarified. We herein report a case of SC with low expression of PD‐L1 and few pre‐existing tumor‐infiltrating lymphocytes which showed a remarkable response to pembrolizumab plus cytotoxic chemotherapy as first‐line treatment. Our findings suggest that combined treatment might enhance the immunogenic response, even in immunologically ignored SCs.Keywords
This publication has 18 references indexed in Scilit:
- Classifying Cancers Based on T-cell Infiltration and PD-L1Cancer Research, 2015
- Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung CancerJNCI Journal of the National Cancer Institute, 2015
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lungLung Cancer, 2014
- Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid CarcinomaJournal of Thoracic Oncology, 2013
- Effects of conventional therapeutic interventions on the number and function of regulatory T cellsOncoImmunology, 2013
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyThe Journal of Experimental Medicine, 2006